Best for
Mobile
How to buy Novartis shares | $96.9
Own Novartis shares in just a few minutes.
Novartis AG is a drug manufacturers-general business based in the US. Novartis shares (NVS.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $96.9 – an increase of 1.33% over the previous week. Novartis employs 110,000 staff and has a trailing 12-month revenue of around $49.6 billion.
How to buy shares in Novartis
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: NVS in this case.
- Research Novartis shares. The platform should provide the latest information available.
- Buy your Novartis shares. It's that simple.
What's in this guide?
- Can I buy shares in Novartis?
- Novartis shares summary
- Compare share dealing platforms
- Is Novartis stock a buy or sell?
- Novartis performance over time
- Can I short Novartis shares?
- Are Novartis shares over-valued?
- Novartis's financials
- How volatile are Novartis shares?
- Does Novartis pay a dividend?
- Have Novartis shares ever split?
- Other common questions
Novartis share price
Use our graph to track the performance of NVS stocks over time.Novartis shares at a glance
Information last updated 2021-01-23.
| Latest market close | $96.9 |
|---|---|
| 52-week range | $69.1801 - $97.52 |
| 50-day moving average | $92.747 |
| 200-day moving average | $87.7848 |
| Wall St. target price | $107 |
| PE ratio | 31.3897 |
| Dividend yield | $3.09 (3.19%) |
| Earnings per share (TTM) | $3.087 |
Invest in Novartis shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Novartis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Novartis price performance over time
Historical closes compared with the last close of $95.81
| 1 week (2021-01-19) | -0.91% |
|---|---|
| 1 month (2020-12-24) | 8.20% |
| 3 months (2020-10-26) | 13.82% |
| 6 months (2020-07-24) | 13.76% |
| 1 year (2020-01-24) | 2.07% |
|---|---|
| 2 years (2019-01-25) | 24.40% |
| 3 years (2018-01-26) | 13.86% |
| 5 years (2016-01-26) | 29.39% |
Is Novartis under- or over-valued?
Valuing Novartis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novartis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novartis's P/E ratio
Novartis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Novartis shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Novartis's PEG ratio
Novartis's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9532. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novartis's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novartis's EBITDA
Novartis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $18.2 billion.
The EBITDA is a measure of a Novartis's overall financial performance and is widely used to measure a its profitability.
Novartis financials
| Revenue TTM | $49.6 billion |
|---|---|
| Operating margin TTM | 27.25% |
| Gross profit TTM | $34.7 billion |
| Return on assets TTM | 6.88% |
| Return on equity TTM | 13.25% |
| Profit margin | 14.33% |
| Book value | $23.954 |
| Market capitalisation | $220.7 billion |
TTM: trailing 12 months
How to short and sell Novartis shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "NVS.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 4.4 million Novartis shares held short by investors – that's known as Novartis's "short interest". This figure is 11.5% up from 4.0 million last month.
There are a few different ways that this level of interest in shorting Novartis shares can be evaluated.
Novartis's "short interest ratio" (SIR)
Novartis's "short interest ratio" (SIR) is the quantity of Novartis shares currently shorted divided by the average quantity of Novartis shares traded daily (recently around 1.9 million). Novartis's SIR currently stands at 2.31. In other words for every 100,000 Novartis shares traded daily on the market, roughly 2310 shares are currently held short.
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novartis.
Find out more about how you can short Novartis stock.
Novartis share dividends
Dividend payout ratio: 53.6% of net profits
Recently Novartis has paid out, on average, around 53.6% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.19% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novartis shareholders could enjoy a 3.19% return on their shares, in the form of dividend payments. In Novartis's case, that would currently equate to about $3.09 per share.
Novartis's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novartis's most recent dividend payout was on 12 March 2020. The latest dividend was paid out to all shareholders who bought their shares by 3 March 2020 (the "ex-dividend date").
Have Novartis's shares ever split?
Novartis's shares were split on a 1116:1000 basis on 9 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1116 shares. This wouldn't directly have changed the overall worth of your Novartis shares – just the quantity. However, indirectly, the new 10.4% lower share price could have impacted the market appetite for Novartis shares which in turn could have impacted Novartis's share price.
Novartis share price volatility
Over the last 12 months, Novartis's shares have ranged in value from as little as $69.1801 up to $97.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novartis's is 0.5393. This would suggest that Novartis's shares are less volatile than average (for this exchange).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Novartis overview
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; Dyno Therapeutics Inc.; and Olema Oncology. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Frequently asked questions
More guides on Finder
-
How to buy Novartis shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Novartis shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert